Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_John Gabrielson_2023
VIEWPOINTS

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots: John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disordersUnder the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023

Read more

Insights+ Key Biosimilars Events of May 2022
INSIGHTS+

Insights+ Key Biosimilars Events of May 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of May, JSR Life Sciences launches Similis Bio business…
June 2, 2022

Read more